Exagen director granted 37,500 stock options

EXAGEN INC. director Scott D. Kahn reported receiving a stock option grant covering 37,500 shares of common stock.

Rhea-AI Filing Summary

EXAGEN INC. director Scott D. Kahn reported receiving a stock option grant covering 37,500 shares of common stock. The option has an exercise price of $4.31 per share and expires on June 8, 2036.

According to the terms, all 37,500 option shares become fully vested and exercisable on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, as long as Kahn continues to serve on the board through that date. After this grant, he directly holds options on 46,500 shares.

Insider Trade Summary

Grant/Award: 37,500 shares

Grant/Award 1 txn

Insider KAHN SCOTT D

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option(right to buy)	37,500	$0.00	$0.00

Holdings After Transaction: Stock Option(right to buy) — 46,500 contracts (Direct)

Footnotes (1)

1. F1. The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Key Figures

Option grant size: 37,500 shares Exercise price: $4.31 per share Expiration date: June 8, 2036 +2 more

5 metrics

Option grant size 37,500 shares Stock option covering common stock

Exercise price <money>$4.31</money> per share Strike price for granted options

Expiration date <date>June 8, 2036</date> Option term end

Underlying shares 37,500 shares Common stock underlying new option

Options held after grant 46,500 shares Total derivative holdings following transaction

Key Terms

Stock Option(right to buy), exercise price, vesting, annual meeting of the Issuer's stockholders, +1 more

5 terms

Stock Option(right to buy) financial

"security_title: Stock Option(right to buy)"

exercise price financial

"conversion_or_exercise_price: 4.3100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"becomes fully vested and exercisable on the first to occur"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of the Issuer's stockholders financial

"or (b) the next occurring annual meeting of the Issuer's stockholders"

board of directors financial

"continued service on the board of directors of the Issuer"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Exagen (XGN) director Scott D. Kahn report in this Form 4?

Scott D. Kahn reported receiving a stock option grant for 37,500 shares of Exagen common stock. These options were granted as a compensation-related award and are not an open-market purchase or sale of existing shares.

What are the key terms of Scott D. Kahn’s new Exagen (XGN) stock options?

The options cover 37,500 shares of Exagen common stock with an exercise price of $4.31 per share. They expire on June 8, 2036, giving Kahn a long window to exercise once vested.

When do Scott D. Kahn’s Exagen (XGN) options vest and become exercisable?

All 37,500 option shares vest and become exercisable on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, assuming Kahn continues serving on Exagen’s board through that vesting date.

How many Exagen (XGN) option shares does Scott D. Kahn hold after this transaction?

After the grant, Kahn directly holds options on 46,500 shares of Exagen common stock. This Form 4 reflects his updated derivative holdings following the new award.

Is Scott D. Kahn buying or selling Exagen (XGN) stock in this Form 4?

The filing shows a grant of stock options, not a market buy or sell. It is categorized as a grant or award acquisition, meaning it is part of Kahn’s director compensation rather than an open-market trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 01:38 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KAHN SCOTT D

(Last) (First) (Middle)

C/O EXAGEN INC.

1261 LIBERTY WAY

(Street)

VISTA CALIFORNIA 92081

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
EXAGEN INC. [ XGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option(right to buy)	$4.31	06/09/2026		A		37,500		06/09/2026	06/08/2036(1)	Common Stock	37,500	$0	46,500	D

Explanation of Responses:

1. The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Remarks:

	/s/ Jeffrey G. Black, as attorney-in-fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)